GT Biopharma Finalizes 1-for-25 Reverse Split Effective Sept 8 to Regain Nasdaq Compliance
GTBP is trading near its 52-week low of $0.261 (7.9% above the low) on light trading volume (0.1× avg).
Summary
GT Biopharma filed the final terms of its 1-for-25 reverse stock split, effective September 8, 2026, reducing shares outstanding to ~1.8 million and authorized shares to 26.5 million to regain Nasdaq compliance.
Key Events · Corporate Governance and Compliance · GTBP
-
1-for-25 Reverse Split Finalized
Board approved the final 1-for-25 ratio on August 27, 2026, effective September 8, 2026 at 12:01 a.m. ET. Outstanding shares drop from ~45,109,497 to ~1,804,379.
-
Authorized Shares Cut 90%
Simultaneous reduction of authorized capital stock from 265,000,000 to 26,500,000 shares (25,000,000 common + 1,500,000 preferred).
-
11 Preferred Series Eliminated
Certificates of Elimination filed for Series A through K preferred stock; no shares of any eliminated series were outstanding immediately before filing.
-
Nasdaq Compliance Objective
The split is designed to raise the per-share price above Nasdaq's $1.00 minimum bid requirement, addressing delisting risk previously disclosed in the August 10-Q.
Analysis · GTBP · Life Sciences
The final terms of GT Biopharma's reverse stock split are now locked in: a 1-for-25 ratio effective September 8, 2026, reducing outstanding shares from roughly 45.1 million to 1.8 million. The board also cut authorized shares from 265 million to 26.5 million and eliminated 11 series of preferred stock. This is the concrete execution of the shareholder-approved plan to lift the stock price above Nasdaq's $1.00 minimum bid requirement — a critical step to avoid delisting. The split itself does not change the company's market value, but it directly addresses the listing risk that has been hanging over the stock since the going-concern and delisting warnings in the August 10-Q.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.3% of the 1324 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GTBP was trading at $0.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.7M. The 52-week trading range was $0.26 to $1.37. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.